ストックスクリーナーアプリを入手
26.11
12.20%
2.84
アフターアワーズ：
25.70
-0.41
-1.57%
前日終値:
$23.27
開ける：
$23.27
24時間の取引高:
1.67M
Relative Volume:
2.32
時価総額：
$1.40B
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+24.27%
1か月 パフォーマンス:
+32.00%
6か月 パフォーマンス:
+64.21%
1年 パフォーマンス:
+262.14%
1日の値動き範囲:
$23.01
$27.24
1週間の範囲:
$20.56
$27.24
52週間の値動き範囲:
$6.11
$44.60
Zenas Biopharma Inc Stock (ZBIO) Company Profile
名前
Zenas Biopharma Inc
セクター
電話
857-271-2954
住所
852 WINTER STREET, SUITE 250, WALTHAM
Compare ZBIO vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
26.11 | 1.25B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-20 | 開始されました | Wedbush | Outperform |
| 2025-02-04 | 開始されました | Wolfe Research | Outperform |
| 2024-12-16 | 開始されました | H.C. Wainwright | Buy |
| 2024-11-05 | 開始されました | Rodman & Renshaw | Buy |
| 2024-10-08 | 開始されました | Citigroup | Buy |
| 2024-10-08 | 開始されました | Guggenheim | Buy |
| 2024-10-08 | 開始されました | Jefferies | Buy |
| 2024-10-08 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Zenas Biopharma Inc (ZBIO) 最新ニュース
Zenas BioPharma (NASDAQ:ZBIO) Trading 13.8% HigherWhat's Next? - MarketBeat
ZBIO: Obexelimab shows strong efficacy, safety, and commercial promise in IgG4-RD and beyond - TradingView
Zenas BioPharma’s MS drug shows 95% reduction in brain lesions By Investing.com - Investing.com Nigeria
HC Wainwright Reiterates Buy Rating for Zenas BioPharma (NASDAQ:ZBIO) - MarketBeat
Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone ... - Bluefield Daily Telegraph
Zenas BioPharma Announces Late-Breaking Platform - GlobeNewswire
Insider Trends: Can Zenas BioPharma Inc be the next market leaderJuly 2025 Decliners & Entry Point Confirmation Alerts - baoquankhu1.vn
Zenas BioPharma (ZBIO) Price Target Increased by 10.51% to 44.44 - MSN
Does Zenas BioPharma (ZBIO) CEO’s Million‑Dollar Share Buy Reframe Management Credibility After Recent Setbacks? - Sahm
A Look At Zenas BioPharma (ZBIO) Valuation After Positive Phase 3 INDIGO Data And CEO Share Purchase - Sahm
Commit To Purchase Zenas Biopharma At $12.50, Earn 21.9% Annualized Using Options - Nasdaq
Zenas Bio rises after insider purchase by CEO (ZBIO:NASDAQ) - Seeking Alpha
Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - marketscreener.com
Zenas BioPharma, Inc. (NASDAQ:ZBIO) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Zenas BioPharma (ZBIO) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
A Big Boss Bet on Zenas BioPharma’s Future - TipRanks
Zenas BioPharma (NASDAQ:ZBIO) CEO Buys 57,000 Shares - MarketBeat
Zenas BioPharma (NASDAQ:ZBIO) Shares Up 8.9%Here's Why - MarketBeat
Chipmakers Recap: What is the target price for Zenas BioPharma Inc stockJuly 2025 Catalysts & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zenas BioPharma, Inc. – ZBIO - Chartmill
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zenas BioPharma, Inc. – ZBIO - GlobeNewswire Inc.
Zenas BioPharma, Inc. (NASDAQ:ZBIO) Short Interest Up 27.4% in January - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Zenas BioPharma, Inc. (ZBIO) And Encourages Shareholders to Reach Out - ACCESS Newswire
Published on: 2026-02-01 19:33:40 - baoquankhu1.vn
Investment Report: What are analysts price targets for ArrowMark Financial CorpWeekly Investment Summary & Daily Stock Momentum Reports - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Is Zenas BioPharma Inc.’s growth already priced in2025 Top Gainers & Safe Entry Trade Reports - mfd.ru
Zenas BioPharma, Inc. (ZBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - accessnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc.ZBIO - Chartmill
Zenas BioPharma Slams Investor's Revamped Fraud Claim - Law360
Can Zenas BioPharma Inc be the next market leaderOptions Play & Short-Term High Return Strategies - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Zenas BioPharma (ZBIO) Stock Analysis: Promising 99.75% Upside Potential For Investors - DirectorsTalk Interviews
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zenas BioPharma, Inc. (ZBIO) And Encourages Investors to Connect - accessnewswire.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zenas BioPharma, Inc. (ZBIO) And Encourages Shareholders to Connect - ACCESS Newswire
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc.ZBIO - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zenas BioPhar - The National Law Review
Zenas BioPharma (NASDAQ:ZBIO) Trading Down 6.6%Here's Why - MarketBeat
Zenas Bio rises as Wedbush launches with Outperform on lead asset - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Robbins LLP Reminds ZBIO Stockholders with Large Losses to Contac - The National Law Review
Zenas BioPharma Announces Inducement Grant under Nasdaq Listing Rule 5635(4) - marketscreener.com
Zenas BioPharma, Inc. (ZBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - accessnewswire.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Investors to Learn More About the Investigation - accessnewswire.com
Zenas crashes as late-stage trial data for lead asset disappoint - MSN
Portfolio Update: Will Zenas BioPharma Inc outperform during market ralliesWeekly Loss Report & AI Forecast Swing Trade Picks - baoquankhu1.vn
Moving Averages: Can Northann Corp navigate macro headwindsPortfolio Return Summary & Comprehensive Market Scan Reports - baoquankhu1.vn
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zenas BioPharma (NASDAQ:ZBIO) Stock Price Down 7.1%Time to Sell? - MarketBeat
Zenas BioPharma Stock Pre-Market (-4.4%): Shareholder Lawsuit Investigation Announced - Trefis
Assessing Zenas BioPharma (ZBIO) Valuation After Phase 3 INDIGO Success And CEO Share Purchase - Sahm
Zenas Biopharma Inc (ZBIO) 財務データ
Zenas Biopharma Inc (ZBIO) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):